These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 39085079)

  • 1. Structure-Activity Relationship Study of CYM51010, an agonist for the µ-δ Opioid Receptor Heterodimer.
    Watanabe A; Yamada S; Yoshida H; Inagaki M; Atsumi N; Matsushima A; Takahashi N; Ishibashi N; Ogino T; Someya R; Taguchi A; Kagaya R; Ashizawa K; Mendori H; Karasawa Y; Ohshima K; Yokoyama A; Nonaka M; Miyano K; Karaki F; Hirayama S; Itoh K; Uezono Y; Fujii H
    Chem Pharm Bull (Tokyo); 2024; 72(7):711-730. PubMed ID: 39085079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Phenethyl Substitution in 14-Methoxy-N-methylmorphinan-6-ones Turns Selective µ Opioid Receptor Ligands into Dual µ/δ Opioid Receptor Agonists.
    Dumitrascuta M; Bermudez M; Ben Haddou T; Guerrieri E; Schläfer L; Ritsch A; Hosztafi S; Lantero A; Kreutz C; Massotte D; Schmidhammer H; Wolber G; Spetea M
    Sci Rep; 2020 Mar; 10(1):5653. PubMed ID: 32221355
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mu and Delta Opioid Receptors Are Coexpressed and Functionally Interact in the Enteric Nervous System of the Mouse Colon.
    DiCello JJ; Carbone SE; Saito A; Rajasekhar P; Ceredig RA; Pham V; Valant C; Christopoulos A; Veldhuis NA; Canals M; Massotte D; Poole DP
    Cell Mol Gastroenterol Hepatol; 2020; 9(3):465-483. PubMed ID: 31759144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and Structure-Activity Relationships of 5'-Aryl-14-alkoxypyridomorphinans: Identification of a μ Opioid Receptor Agonist/δ Opioid Receptor Antagonist Ligand with Systemic Antinociceptive Activity and Diminished Opioid Side Effects.
    Vekariya RH; Lei W; Ray A; Saini SK; Zhang S; Molnar G; Barlow D; Karlage KL; Bilsky EJ; Houseknecht KL; Largent-Milnes TM; Streicher JM; Ananthan S
    J Med Chem; 2020 Jul; 63(14):7663-7694. PubMed ID: 32530286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and evaluation of 4-substituted piperidines and piperazines as balanced affinity μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist ligands.
    Bender AM; Clark MJ; Agius MP; Traynor JR; Mosberg HI
    Bioorg Med Chem Lett; 2014 Jan; 24(2):548-51. PubMed ID: 24365161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further Optimization and Evaluation of Bioavailable, Mixed-Efficacy μ-Opioid Receptor (MOR) Agonists/δ-Opioid Receptor (DOR) Antagonists: Balancing MOR and DOR Affinities.
    Harland AA; Yeomans L; Griggs NW; Anand JP; Pogozheva ID; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2015 Nov; 58(22):8952-69. PubMed ID: 26524472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Novel Mu-Delta Opioid Agonist Demonstrates Enhanced Efficacy With Reduced Tolerance and Dependence in Mouse Neuropathic Pain Models.
    Lei W; Vekariya RH; Ananthan S; Streicher JM
    J Pain; 2020; 21(1-2):146-160. PubMed ID: 31201990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist.
    Pasquinucci L; Turnaturi R; Calò G; Pappalardo F; Ferrari F; Russo G; Arena E; Montenegro L; Chiechio S; Prezzavento O; Parenti C
    Eur J Med Chem; 2019 Apr; 168():189-198. PubMed ID: 30822708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aromatic-Amine Pendants Produce Highly Potent and Efficacious Mixed Efficacy μ-Opioid Receptor (MOR)/δ-Opioid Receptor (DOR) Peptidomimetics with Enhanced Metabolic Stability.
    Henry S; Anand JP; Twarozynski JJ; Brinkel AC; Pogozheva ID; Sears BF; Jutkiewicz EM; Traynor JR; Mosberg HI
    J Med Chem; 2020 Feb; 63(4):1671-1683. PubMed ID: 31986033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-analgesic effect of the mu/delta opioid receptor heteromer revealed by ligand-biased antagonism.
    Milan-Lobo L; Enquist J; van Rijn RM; Whistler JL
    PLoS One; 2013; 8(3):e58362. PubMed ID: 23554887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu/Delta Opioid Ligands for the Treatment of Pain.
    Nastase AF; Griggs NW; Anand JP; Fernandez TJ; Harland AA; Trask TJ; Jutkiewicz EM; Traynor JR; Mosberg HI
    ACS Chem Neurosci; 2018 Jul; 9(7):1840-1848. PubMed ID: 29677442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of novel LP1-based analogues with enhanced delta opioid receptor profile.
    Pasquinucci L; Turnaturi R; Prezzavento O; Arena E; Aricò G; Georgoussi Z; Parenti R; Cantarella G; Parenti C
    Bioorg Med Chem; 2017 Sep; 25(17):4745-4752. PubMed ID: 28734666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress in the development of more effective and safer analgesics for pain management.
    Turnaturi R; Chiechio S; Salerno L; Rescifina A; Pittalà V; Cantarella G; Tomarchio E; Parenti C; Pasquinucci L
    Eur J Med Chem; 2019 Dec; 183():111701. PubMed ID: 31550662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment.
    Pasquinucci L; Parenti C; Turnaturi R; Aricò G; Marrazzo A; Prezzavento O; Ronsisvalle S; Georgoussi Z; Fourla DD; Scoto GM; Ronsisvalle G
    Life Sci; 2012 Jan; 90(1-2):66-70. PubMed ID: 22100511
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parallel Synthesis of Hexahydrodiimidazodiazepines Heterocyclic Peptidomimetics and Their in Vitro and in Vivo Activities at μ (MOR), δ (DOR), and κ (KOR) Opioid Receptors.
    Eans SO; Ganno ML; Mizrachi E; Houghten RA; Dooley CT; McLaughlin JP; Nefzi A
    J Med Chem; 2015 Jun; 58(12):4905-17. PubMed ID: 25996309
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Affinity, potency, efficacy, selectivity, and molecular modeling of substituted fentanyls at opioid receptors.
    Eshleman AJ; Nagarajan S; Wolfrum KM; Reed JF; Nilsen A; Torralva R; Janowsky A
    Biochem Pharmacol; 2020 Dec; 182():114293. PubMed ID: 33091380
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biased Opioid Ligands.
    Faouzi A; Varga BR; Majumdar S
    Molecules; 2020 Sep; 25(18):. PubMed ID: 32948048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 14-amino, 14-alkylamino, and 14-acylamino analogs of oxymorphindole. Differential effects on opioid receptor binding and functional profiles.
    Grundt P; Jales AR; Traynor JR; Lewis JW; Husbands SM
    J Med Chem; 2003 Apr; 46(8):1563-6. PubMed ID: 12672258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Asymmetric synthesis and in vitro and in vivo activity of tetrahydroquinolines featuring a diverse set of polar substitutions at the 6 position as mixed-efficacy μ opioid receptor/δ opioid receptor ligands.
    Bender AM; Griggs NW; Anand JP; Traynor JR; Jutkiewicz EM; Mosberg HI
    ACS Chem Neurosci; 2015 Aug; 6(8):1428-35. PubMed ID: 25938166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two delta opioid receptor subtypes are functional in single ventral tegmental area neurons, and can interact with the mu opioid receptor.
    Margolis EB; Fujita W; Devi LA; Fields HL
    Neuropharmacology; 2017 Sep; 123():420-432. PubMed ID: 28645621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.